TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02317029

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia during cardioversion
Description: Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioversion with a biphasic truncated exponential waveform
Description: Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion with a biphasic truncated exponential waveform
Description: Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperoxia during cardioversion
Description: Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia during cardioversion
Description: Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
Study: NCT04350450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg tablet
Study: NCT02604212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Study: NCT00022165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Study: NCT02604212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03974711

Intervention type: OTHER
Intervention: In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort.
Description: There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
Study: NCT00003556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-hB7.1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: canarypox-hIL-12 melanoma vaccine
Study: NCT02572869

Intervention type: OTHER
Intervention: physical exam
Description: Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes.
Study: NCT04470349

Intervention type: DEVICE
Intervention: LITOS
Description: Patients who received a LITOS dynamic distraction system after 31.12.2017

Intervention type: DEVICE
Intervention: Ligamentotaxor
Description: Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
Study: NCT01566006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
Study: NCT02730299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiCord® (omidubicel)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord Blood Unit
Description: Cord blood unit
Study: NCT03834142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSS-2 Bridge
Description: The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
Study: NCT00381914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU vitamin D / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 800 IU vitamin D / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1200 IU vitamin D / day
Study: NCT02256410

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
Study: NCT04382521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Intervention
Description: Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Message Intervention
Description: Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
Study: NCT05094479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health information delivered via health app
Description: Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
Study: NCT02231762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Description: Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
Study: NCT02111655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Second generation surveillance of AVF
Description: Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vital signs
Description: Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
Study: NCT00743184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozarelix
Description: One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozarelix
Description: One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
Study: NCT03080506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Description: Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
Study: NCT04091451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
Description: 2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
Study: NCT05021666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group
Study: NCT03293316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Random Noise Stimulation
Description: The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
Study: NCT02210624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYNR-CS inj.
Description: Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
Study: NCT00706589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Initial dose : 2mg, Maximum dose : 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Initial dose: 2mg, Maximum dose:20mg
Study: NCT02111655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vital signs
Description: Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session

Intervention type: PROCEDURE
Group type: OTHER
Intervention: physical examination of AVF
Description: Predialysis physical examination of AVF every dialysis session.
Study: NCT01325844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: 0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
Study: NCT03008317

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PEEK
Description: a metallic denture base

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK
Description: a metallic denture base
Study: NCT04206969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcultural psychotherapy
Description: In addition to usual care, the participants receive transcultural psychotherapy
Study: NCT02111655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical examination of AVF
Description: Predialysis physical examination of AVF every dialysis session.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ktv test
Description: Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
Study: NCT03639818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual sessions of cognitive remediation
Description: The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
Study: NCT04492592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Workshop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS/Texting
Description: SMS/Texting
Study: NCT02418689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV120101 (Poziotinib)
Description: NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
Study: NCT04492592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS/Texting
Description: SMS/Texting
Study: NCT04556786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitions of care
Description: The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
Study: NCT03581591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
Study: NCT01753297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin 11.25 mg
Description: Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
Study: NCT00593905

Intervention type: DRUG
Intervention: Sitaxsentan
Description: Sitaxsentan sodium 100 mg tablet every morning

Intervention type: DRUG
Intervention: Bosentan, Ambrisentan
Description: Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
Study: NCT01119664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 721015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 721015
Study: NCT02111655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ktv test
Description: Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: urea method
Description: Quarterly recirculation with urea method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urea method
Description: Quarterly recirculation with urea method.
Study: NCT04542668

Intervention type: OTHER
Group type: OTHER
Intervention: Cycling then running
Description: Ergometer cycling Treadmill running

Intervention type: OTHER
Group type: OTHER
Intervention: Running then cycling
Description: Treadmill running Ergometer cycling

Intervention type: OTHER
Group type: OTHER
Intervention: Inotropy
Description: Adrenaline induced inotropy

Intervention type: OTHER
Group type: OTHER
Intervention: Inotropy
Description: Adrenaline induced inotropy

Intervention type: OTHER
Group type: OTHER
Intervention: Resting
Description: Subjects must be minimally physically active

Intervention type: OTHER
Group type: OTHER
Intervention: Resting
Description: Subjects must be minimally physically active
Study: NCT05563116

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography coronary artery calcium (CAC) score (part of routine workup)
Description: Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography coronary artery calcium (CAC) score (part of routine workup)
Description: Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
Study: NCT02009293

Intervention type: OTHER
Intervention: Cough monitor
Description: questionnaires about cough and quality of life
Study: NCT01741714

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham chiropractic manipulative therapy
Description: Sham manipulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic spinal manipulative therapy
Description: Chiropractic spinal manipulative therapy
Study: NCT03090074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet regime
Description: Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet regime
Description: Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet regime
Description: Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet regime
Description: Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Type of psychological support
Description: Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Type of psychological support
Description: Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Type of psychological support
Description: Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Type of psychological support
Description: Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
Study: NCT00601861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: Fixed and equal dose for s.c. injection, 3 times weekly
Study: NCT01920763

Intervention type: OTHER
Intervention: Clinical Measurement
Description: No direct interventions; study is observational and clinical assessments only will be performed.